调神解郁针法结合康复训练治疗卒中后抑郁的临床研究

注册号:

Registration number:

ITMCTR2100004588

最近更新日期:

Date of Last Refreshed on:

2021-03-18

注册时间:

Date of Registration:

2021-03-18

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

调神解郁针法结合康复训练治疗卒中后抑郁的临床研究

Public title:

A Clinical Study on the Treatment of Post-stroke Depression by Acupuncture combined with Rehabilitation Training

注册题目简写:

English Acronym:

研究课题的正式科学名称:

调神解郁针法结合康复训练治疗卒中后抑郁的临床研究

Scientific title:

A Clinical Study on the Treatment of Post-stroke Depression by Acupuncture combined with Rehabilitation Training

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100044436 ; ChiMCTR2100004588

申请注册联系人:

谢文霞

研究负责人:

谢文霞

Applicant:

Wenxia Xie

Study leader:

Wenxia Xie

申请注册联系人电话:

Applicant telephone:

+86 13868653068

研究负责人电话:

Study leader's telephone:

+86 13868653068

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wcgxwx@163.com

研究负责人电子邮件:

Study leader's E-mail:

wcgxwx@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

浙江省温州市瓯海区南白象温医一院新院区

研究负责人通讯地址:

浙江省温州市瓯海区南白象温医一院新院区

Applicant address:

Nanbaixiang Wenyi First Hospital, Ouhai District, Wenzhou, Zhejiang, China

Study leader's address:

Nanbaixiang Wenyi First Hospital, Ouhai District, Wenzhou, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

325000

研究负责人邮政编码:

Study leader's postcode:

325000

申请人所在单位:

温州医科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Wenzhou Medical University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

YS2020-285

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

温州医科大学附属第一医院临床研究专业伦理委员会

Name of the ethic committee:

Ethics Committee of clinical research in the First Affiliated Hospital of Wenzhou Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020/11/17 0:00:00

伦理委员会联系人:

吴高俊

Contact Name of the ethic committee:

Gaojun Wu

伦理委员会联系地址:

浙江省温州市瓯海区南白象温医一院新院区

Contact Address of the ethic committee:

Nanbaixiang Wenyi First Hospital, Ouhai District, Wenzhou, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 13868653068

伦理委员会联系人邮箱:

Contact email of the ethic committee:

wcgxwx@163.com

研究实施负责(组长)单位:

温州医科大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Wenzhou Medical University

研究实施负责(组长)单位地址:

浙江省温州市瓯海区南白象温医一院新院区

Primary sponsor's address:

Nanbaixiang Wenyi First Hospital, Ouhai District, Wenzhou, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

温州

Country:

China

Province:

Zhejiang

City:

Wenzhou

单位(医院):

温州医科大学附属第一医院

具体地址:

瓯海区南白象温医一院新院区

Institution
hospital:

The First Affiliated Hospital of Wenzhou Medical University

Address:

Nanbaixiang Wenyi First Hospital, Ouhai District

经费或物资来源:

浙江省中医药科技计划

Source(s) of funding:

Science and technology plan of traditional Chinese medicine in Zhejiang Province

研究疾病:

卒中后抑郁

研究疾病代码:

Target disease:

Post-stroke Depression

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

1. 探讨调神解郁针法联合康复治疗对PSD患者情绪状态改善情况,日常生活活动能力以及早期社区生活的影响。 2. 研究调神解郁针法的临床疗效与机理。

Objectives of Study:

To explore the effect of mind regulating and depression relieving acupuncture combined with rehabilitation therapy on the improvement of the emotional state, activities of daily living and early community life of PSD patients.To study the clinical efficacy and mechanism of Tiaoshen Jieyu acupuncture.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

① 符合脑卒中和抑郁症中、西医诊断标准; ② 年龄 30~75 岁; ③ 生命体征平稳,意识清楚,有基本表达和沟通能力,能接受量表评估; ④ 病程为 2~36 周; ⑤ 无抗抑郁药物使用史; ⑥ HAMD-17 评分为7~24 分; ⑦ 患者或家属同意参与本研究,并自愿签署知情同意书。

Inclusion criteria

1. Meet the diagnostic criteria of Chinese and Western medicine for stroke and depression; 2. Aged 30-75 years old; 3. they had stable vital signs, clear consciousness, basic expression and communication skills, and could be evaluated by the scale; 4. the course of disease was 2-36 weeks; 5. they had no history of antidepressant use; 6. the HAMD-17 score was 7-24 points; 7. the patients or their families agreed to participate in the study and voluntarily signed the informed consent.

排除标准:

①重度抑郁症者(HAMD-17 总分≥25 分),或有严重自杀倾向者; ②生命体征不稳定或有精神分裂症、躁狂症等精神疾病者; ③合并严重的心、肝、肾功能衰竭,恶性肿瘤等疾病者; ④伴明显听力、语言、认知功能障碍,查体及评估不能配合者。

Exclusion criteria:

1. Patients with severe depression (HAMD-17 total score >=25), or severe suicidal tendency; 2. patients with unstable vital signs, schizophrenia, mania and other mental diseases; 3. patients with severe heart, liver, kidney failure, malignant tumor and other diseases; 4. patients with obvious hearing, speech and cognitive impairment, and physical examination and evaluation can not cooperate.

研究实施时间:

Study execute time:

From 2020-09-01

To      2023-08-31

征募观察对象时间:

Recruiting time:

From 2021-03-17

To      2023-06-30

干预措施:

Interventions:

组别:

治疗组

样本量:

50

Group:

Group 1

Sample size:

干预措施:

调神解郁针法联合常规康复训练

干预措施代码:

Intervention:

Tiaoshen Jieyu Acupuncturecombined with Rehabilitation Training

Intervention code:

组别:

对照组

样本量:

50

Group:

Group 2

Sample size:

干预措施:

康复训练

干预措施代码:

Intervention:

Rehabilitation Training

Intervention code:

样本总量 Total sample size : 100

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

浙江

市(区县):

温州

Country:

China

Province:

Zhejiang

City:

Wenzhou

单位(医院):

温州医科大学附属第一医院

单位级别:

三级甲等

Institution/hospital:

The First Affiliated Hospital of Wenzhou Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

安全性评价

指标类型:

次要指标

Outcome:

Safety evaluation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日常活动功能评价

指标类型:

主要指标

Outcome:

Functional evaluation of daily activities

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

依从性评价

指标类型:

次要指标

Outcome:

Compliance evaluatio

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁程度评价

指标类型:

主要指标

Outcome:

Depression Leve

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

静脉血

Sample Name:

Blood

Tissue:

venous blood

人体标本去向

使用后销毁

说明

1年

Fate of sample 

Destruction after use

Note:

One Year

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 30
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用SPSS软件将100例患者随机分成2组(试验组和对照组)

Randomization Procedure (please state who generates the random number sequence and by what method):

100 patients were randomly divided into 2 groups using SPSS software(Group Treatment and Group Control).

盲法:

盲法评价、盲法统计(结果评估人员和统计人员由不知道分组信息的人员担任)。

Blinding:

Blind evaluation,blind statistics(the assessment and statistical personnel do not know about the group information.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023.08.31数据公开 请说明共享原始数据的方式

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Aug.31st, 2023.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

填写病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统